Vaborem
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus neque ipsum, blandit vitae urna et, facilisis porta lorem. Donec vel bibendum urna, in tincidunt ex. Vestibulum rhoncus pellentesque nisl sed tristi
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio, neque qui velit. Magni dolorum quidem ipsam eligendi, totam, facilis laudantium cum accusamus ullam voluptatibus commodi numquam, error, est. Ea, consequatur.
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio, neque qui velit. Magni dolorum quidem ipsam eligendi, totam, facilis laudantium cum accusamus ullam voluptatibus commodi numquam, error, est. Ea, consequatur.
Our Therapy Areas
At A.Menarini, we pride ourselves on working in partnership with our customers to keep abreast of the continual advances in evidence based medicines, identifying opportunities where our products can make a real difference to patients’ lives in both primary and secondary care.
Our Products
Brimica
Eklira
Eklira
Our Products
Tenkasi
Quofenix
Vaborem
Quofenix
Vaborem
Our Products
Adenuric
Our Products
Priligy
Spedra
Spedra
Drynol
(bilastine)
- Summary of Product Characteristics Drynol 10mg
- Summary of Product Characteristics Drynol 20mg
- Summary of Product Characteristics Drynol 2.5mg/ml Oral Solution
- Patient Information Leaflet Drynol 10mg
- Patient Information Leaflet Drynol 20mg
- Patient Information Leaflet Drynol 2.5mg/ml Oral Solution
Vokanamet
(canagliflozin/ metformin)
- Summary of Product Characteristics Vokanamet Film coated tablets
- Patient Information Leaflet Vokanamet Film coated tablets
Brimicaâ–¼
(aclinidium bromide/formoterol fumarate dihydrate)
- Summary of Product Characteristics Brimica Genuair 340 micrograms /12 micrograms inhalation powder
- Patient Information Leaflet Brimica Genuair 340 micrograms /12 micrograms inhalation powder
Trinomia
(acetylsalicylic acid/atorvastatin/ ramipril)
- Summary of Product Characteristics Trinomia 40 mg hard capsules
- Summary of Product Characteristics Trinomia 20 mg hard capsules
- Patient Information Leaflet Trinomia 40 mg hard capsules
- Patient Information Leaflet Trinomia 20 mg hard capsules
Konverge
(olmesartan medoxomil /amlodipine)
- Summary of Product Characteristics Konverge film-coated tablets
- Patient Information Leaflet Konverge film-coated tablets
Konverge Plus
(olmesartan medoxomil / amlodipine / hydrochlorothiazide)
- Summary of Product Characteristics Konverge Plus film-coated tablets
- Patient Information Leaflet Konverge Plus film-coated tablets
Omesar Plus
(olmesartan medoxomil/ hydrochlorothiazide)
- Summary of Product Characteristics Omesar Plus 20 mg/12.5 mg & 20 mg/25 mg Film-coated tablets
- Summary of Product Characteristics Omesar Plus 40 mg/12.5 mg & 40 mg/25 mg film-coated tablets
- Patient Information Leaflet Omesar Plus 20 mg/12.5 mg & 20 mg/25 mg Film-coated tablets
- Patient Information Leaflet Omesar Plus 40 mg/12.5 mg & 40 mg/25 mg film-coated tablets
Nebilet Plus
(nebivolol hydrochloride/ hydrochlorothiazide)
- Summary of Product Characteristics Nebilet Plus 5 mg / 12.5 mg film-coated tablets
- Summary of Product Characteristics Nebilet Plus 5 mg / 25 mg film-coated tablets
- Patient Information Leaflet Nebilet Plus 5 mg / 12.5 mg film-coated tablets
- Patient Information Leaflet Nebilet Plus 5 mg / 25 mg film-coated tablets
- Â
Skudexa
(tramadol hydrochloride/ dexketoprofen)
- Summary of Product Characteristics Skudexa 75mg/25mg film coated tablets
- Patient Information Leaflet Skudexa 75mg/25mg film coated tablets
Keral
(dexketoprofen)
- Summary of Product Characteristics Keral 50 mg/2ml Solution for injection/infusion
- Summary of Product Characteristics Keral 25 mg granules for oral solution
- Summary of Product Characteristics Keral 50 mg/2ml Solution for Keral 25mg Film-Coated Tablets
- Patient Information Leaflet Keral 50 mg/2ml Solution for injection/infusion
- Patient Information Leaflet Keral 25 mg granules for oral solution
- Patient Information Leaflet Keral 25mg Film-Coated Tablets
â–¼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Website: www.hpra.ie.
Adverse events should also be reported to A. Menarini Pharmaceuticals Ireland Ltd. Phone no: 01 284 6744.